Get regular updates to your inbox.
Long-term use of the sodium channel blocker phenytoin led to reductions in seizure frequency for four male patients with Dravet syndrome, according to a study in Australia. Weaning off the medication caused seizures to worsen, and re-starting it lowered seizure frequency and improved alertness. The findings are in…
IAMA Therapeutics has signed a second agreement with PsychoGenics to test the effectiveness of new therapy candidates in Dravet syndrome animal models. The companies entered into a service agreement last year to identify the effectiveness of new drug candidates…
New safety and efficacy data from two Phase 1/2a clinical trials testing STK-001, Stoke Therapeutics’ investigational treatment for children and adolescents with Dravet syndrome, are expected as early as mid-year. Interim results from the ongoing Phase 1/2a MONARCH (NCT04442295) and ADMIRAL (ISRCTN99651026) trials, reported late last…
The efficacy and safety of Epidiolex, an oral cannabidiol, in children and adults with Dravet syndrome and Lennox-Gastaut syndrome (LGS) were supported in a real-world setting, with benefits similar to those seen in previous clinical trials and expanded access programs (EAPs), a Spanish EAP study reported. EAPs are…
A novel gene therapy that works to increase the levels of an enzyme called p38-gamma extended survival and reduced seizure activity in a mouse model of Dravet syndrome, a new study reports. “We have tested this therapy extensively, and rigorous assessment by independent labs has confirmed our results,” said…
The Dravet Syndrome Foundation (DSF) has announced the award of $690,000 in total research funding for five projects that aim to improve care for people with Dravet syndrome. The one- to two-year research grants will provide each project funding in amounts ranging from $75,000 to $165,000. Two of…
Up to three years of treatment with Epidiolex in a clinical trial led to sustained reductions in seizure frequency — with the oral cannabidiol generally well-tolerated — in children and adults with seizures associated with tuberous sclerosis complex (TSC). That’s according to final data from an open-label extension…
Combining Xcopri (cenobamate) with existing antiseizure medications may significantly reduce the frequency of seizures in adults with Dravet syndrome, according to a report of four patients. The oral medication — marketed as Ontozry in Europe — reduced the frequency of seizures in all four adults by…
Not only do young people with Dravet syndrome show cognitive, developmental and behavioral differences compared with their normally developing peers, but these differences tend to become more pronounced in adolescence, according to a new study. “Our data indicate that the gap in adaptive function and overall intellectual development between…
STK-001, Stoke Therapeutics’ investigational therapy, continues to show promise in safely reducing seizures among children and adolescents with Dravet syndrome, according to new interim data from the ongoing Phase 1/2a MONARCH and ADMIRAL trials. “We are encouraged by the data from our ongoing studies of STK-001, which continue…
Get regular updates to your inbox.